Change In Japan’s OTC Laws Bodes Changes In Buying Habits
This article was originally published in PharmAsia News
A major change in Japan's laws governing the sale of over-the-counter drugs is expected to lead to a major change in consumer buying habits when it takes effect next April. As of that month, supermarkets and other large retailers are to be allowed to sell OTC drugs, currently confined to pharmacies. A price battle between the two groups is expected to result from relaxation of the pharmaceutical affairs law, placing pressure on drugstores that have seen rapid growth recently, but now face a need to change business models. The law change would remove the current requirement that limits OTC drug sales to pharmacists, allowing regular sales staff to sell the drugs after a year of drug-selling experience and a "registered drug seller" license. (Click here for more - a subscription may be required
You may also be interested in...
TOKYO - While Japan's $70 billion pharmaceutical market is shrinking in value in line with the annual lowering of government health insurance drug prices, one sector is registering growth that industry officials describe as rather unexpected: the over-the-counter market for drugs that treat common colds to traditional Chinese medicines for metabolic syndrome
Amgen has an open road for its Mvasi bevacizumab biosimilar after Genentech’s appeal to enjoin sales, over a notice of commercial marketing technicality, was denied. The US firm continues to weigh up patent-infringement proceedings in separate actions.
Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.